Saving Yvette’s Sight: Vision-Saving Breakthrough By Ivanhoe Broadcast News on May 4, 2026

RALEIGH, NC. (Ivanhoe Newswire) — Most of us take vision for granted. It allows us to read, drive, and recognize faces. But for people with a rare retinal disease called MacTel, that clear center vision can slowly disappear. Now, for the first time, there is a one-time, cell-based implant designed to slow vision loss and help people hold on to their independence. https://www.ivanhoe.com/?p=37013&preview=1&_ppp=ce55ec2df8

Spencer’s Second Chance: Fighting Cancer Without Chemo By Ivanhoe Broadcast News on May 5, 2026

RALEIGH, NC. (Ivanhoe Newswire) — Colorectal cancer is now the second leading cause of cancer deaths in the United States, and rates among adults under 50 continue to rise. While it’s still most common in older adults, it remains one of the deadliest, with the American Cancer Society estimating more than 55,000 deaths this year. For many patients with advanced disease, treatment still relies heavily on chemotherapy, often with tough side effects and repeat infusions. But one young father is now among the first patients in a groundbreaking clinical trial, and his results could help change how this cancer is treated for others. https://www.ivanhoe.com/?p=37017&preview=1&_ppp=198da908e0

Creed’s Comeback: A New Era for Fighting a Rare Childhood Disease By Ivanhoe Broadcast News on May 6, 2026

RALEIGH, NC. (Ivanhoe Newswire) — About one in every 3,500-5,000 boys worldwide is born with Duchenne Muscular Dystrophy, or DMD, a rare genetic condition that causes muscles to weaken over time. For decades, families have been told there was no cure and few treatment options. But today, new treatments and gene-based therapies are beginning to change what life with Duchenne can look like. https://www.ivanhoe.com/?p=37020&preview=1&_ppp=6f18880bb7

Patient Turned Scientist: From Diagnosis to Discovery By Ivanhoe Broadcast News on May 7, 2026

RALEIGH, NC. (Ivanhoe Newswire) — More than 700,000 Americans are living with a brain tumor and treating them is one of medicine’s biggest challenges. Every tumor is different, and doctors often don’t know which drug will work best. Now, a brain cancer survivor is working to change that, not just for himself, but for every patient who comes next. https://www.ivanhoe.com/?p=37023&preview=1&_ppp=2f420b3f2a

Women’s Health Week: Tests Every Mom Should Get By Ivanhoe Broadcast News on May 8, 2026

Orlando, Fla. (Ivanhoe Newswire) — National Women’s Health Week starts May 10th, a reminder for women to put their health first. But a recent survey found more than six in 10 women say they struggle to make their own health a priority. Experts say missing routine screenings can mean missing early warning signs of serious disease https://www.ivanhoe.com/?p=37010&preview=1&_ppp=d8c2cb0184

Immunotherapy for Non-Muscle-Invasive Bladder Cancer: Expert Takeaways From the Latest Updates Authors: Bernadett Szabados, MD; Maria De Santis, MD; Neal D. Shore, MD, FACS

https://www.medscape.org/viewarticle/immunotherapy-non-muscle-invasive-bladder-cancer-expert-2026a10005af?page=1&src=mkmcmr_driv_stan_mscpedu_260430-OUS-HONC-immunotherapy-non-muscle-invasive-bladder-cancer-expert-2026a10005af-cta&uac=148436CN

FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia

https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-antipsychotic-drug-treat-agitation-associated-dementia?utm_medium=email&utm_source=govdelivery FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia The U.S. Food and Drug Administration today approved an expanded use for Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat agitation associated with dementia due to Alzheimer’s disease in adults. The drug is the first FDA-approved treatment for this condition that is not an antipsychotic. FDA initially approved Auvelity in 2022 to treat major depressive disorder in adults. "This approval represents a significant advancement in our ability to help patients and families dealing with one of the most challenging aspects of Alzheimer's disease," said FDA Commissioner Marty Makary, M.D., M.P.H. "With today’s action, patients and their families have access to an additional important treatment for complications of this devastating disease." Agitation is a common and distressing symptom in patients with Alzheimer's disease dementia, characterized by excessive motor activity, or verbal or physical aggression. It can significantly impact quality of life for patients and caregivers. "Auvelity was found to be efficacious for treating agitation in Alzheimer’s disease in two randomized trials and now represents an additional option to address one of the most difficult sequelae of the disease, especially as it progresses,” said Tracy Beth Hoeg, M.D., Ph.D., Acting Director of the FDA’s Center for Drug Evaluation and Research. "We hope this approval will provide meaningful benefit to patients, their families, and caregivers." The first randomized study (NCT 03226522) was a five-week trial in which participants received either Auvelity or a placebo. The primary endpoint was the change from baseline to week five in the total score of the Cohen-Mansfield Agitation Inventory (CMAI), a survey that assesses the frequency of manifestations of agitated behaviors in elderly patients, based on caregiver reports. Auvelity was significantly superior to placebo in The Cohen-Mansfield Agitation Inventory score improvements. The second randomized study (NCT 04947553) was a withdrawal study in participants who responded to Auvelity. Upon reaching a sustained clinical response to Auvelity, patients were randomly assigned to continue treatment with Auvelity or switch to placebo. The primary endpoint was time to relapse. Participants who continued Auvelity treatment had a significantly longer time to relapse of agitation symptoms compared to patients receiving the placebo. The most common side effects include dizziness, upset stomach, headache, diarrhea, drowsiness, dry mouth, sexual dysfunction, and uncontrolled sweating. Auvelity has a Boxed Warning about increased risk of suicidal thoughts and behaviors in adolescents and young adults taking antidepressants. Health care providers should monitor patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during initial treatment. The medicine can cause seizures, with risk increasing with dose. It can also cause elevated blood pressure and hypertension, and may activate mania or hypomania (irritable mood) in susceptible patients. Before starting Auvelity, health care providers should assess blood pressure, screen for personal or family history of bipolar disorder, and determine if patients are taking other medications containing bupropion or dextromethorphan. The FDA granted breakthrough therapy designation and priority review designation for this action. The approval of Auvelity for agitation associated with dementia due to Alzheimer's disease was granted to Axsome Therapeutics.

Brain network alterations in trauma and post-traumatic stress disorder: a systematic review Sarah Imtiaz* [1] , Francesco Panico [1] , Laura Catalano [1] , Rosalia De Biase [1] , Laura Sagliano [1]

https://www.academia.edu/3071-4087/2/2/10.20935/AcadNeurosci8253 Introduction: A substantial body of evidence suggests that traumatic experiences and post-traumatic stress disorder (PTSD) profoundly affect the brain. This systematic review investigates the neurobiological correlates of trauma by synthesizing neuroimaging findings on resting-state activity in PTSD and trauma-exposed participants. By integrating data on regional activity (metabolism/blood flow) and functional connectivity, we aim to distinguish PTSD-specific neural signatures from general trauma-related alterations. We also examine how recent emotional or cognitive engagement may modulate these resting-state patterns. Materials and methods: The electronic databases PubMed, Scopus, and PsycINFO were systematically searched for references on brain correlates of traumatic experiences and PTSD. Target populations included patients with PTSD or individuals exposed to traumatic events without a PTSD diagnosis. References were screened, and the included studies were assessed for quality of evidence. Resting-state functional activation patterns associated with traumatic experiences and PTSD were explored. Results: Seventeen studies were included. These studies highlighted alterations in specific brain networks, such as the default mode network, salience network, and central executive network, in individuals with traumatic experiences and PTSD. Common findings included alterations in the medial prefrontal cortex and the subcortical regions involving the amygdala and the hippocampus in individuals with PTSD. Conclusions: This systematic review underscores the brain activation patterns associated with traumatic experiences and PTSD. The identified alterations in key brain networks provide insights into the neural underpinnings of these conditions and suggest potential targets for future therapeutic interventions. Further research with standardized methodologies and larger cohorts is warranted to confirm these findings and explore their clinical implications. https://www.academia.edu/journals/academia-neuroscience-and-brain-research/articles?source=journal-top-nav

Measles: More Than Just a Rash Adam B. Johnson, MD; Bret A. Nicks, MD, MHA April 22, 2026

https://reference.medscape.com/p11/measles-more-than-just-rash-2026a1000c4q?ecd=wnl_critimg_260501_mscpref_etid8305592&uac=148436CN&impID=8305592

Clinical Pharmacology Corner: FDA Establishes Public Docket Entitled “Obesity and Drug Dosing: Clinical Pharmacology Considerations”

https://www.govinfo.gov/content/pkg/FR-2026-05-01/pdf/2026-08521.pdf?utm_medium=email&utm_source=govdelivery FDA Establishes Public Docket Entitled “Obesity and Drug Dosing: Clinical Pharmacology Considerations” Today, the U.S. Food and Drug Administration (FDA) established a public docket entitled “Obesity and Drug Dosing: Clinical Pharmacology Considerations.” The purpose of this docket is to solicit input on incorporating the assessment of obesity’s effect on drug pharmacokinetics and pharmacodynamics during drug (including biological product) development. These assessments could potentially inform whether obesity impacts the safety and effectiveness of the drug and dosing recommendations for obese patients. FDA invites interested persons to provide detailed information and comments on relevant considerations for evaluating the impact of obesity on drug pharmacokinetics, pharmacodynamics, and the need for specific dosage recommendations. Submit any comments regarding this notice to the public docket (Docket No. FDA-2026-N-3499) until June 30, 2026. Visit the Federal Register notice for additional information on how to comment.